Authors

Amit Mehta, MD

Latest:

Future of R/R DLBCL

A panel of experts discuss the future of R/R DLBCL treatment and review some recent data from the 2022 ASH meeting.

Atrium Health

Latest:

Atrium Health Levine Cancer Begins Treating Patients with Proton Beam Therapy

Atrium Health Levine Cancer will begin treating patients with proton beam therapy.

Lisa Leypoldt, MD

Latest:

Dr Leypoldt on the Use of Isa-KRd in Newly Diagnosed, High-Risk Multiple Myeloma

Lisa Leypoldt, MD, discusses findings from the phase 2 GMMG-CONCEPT trial in patients with multiple myeloma.

Benjamin Margolis, MD, and Julia Fehniger, MD

Latest:

Deciding When to Defer Oncology Treatment

Oncologists are challenged to make a different determination when a new patient presents with advanced cancer.

Cyrus Khan, MD, West Penn Hospital

Latest:

Treating Patients Post CAR T Therapy

David Rizzieri, MD, discusses treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.

Gina Mauro

Vice President of Content,

Latest:

Survey Says: AI Isn’t Going Anywhere in Oncology, But Validity Concerns Remain

Nearly half of oncologists use AI tools for document and communication/editing purposes in their practice, and most foresee an increase in AI integration.

Christine M. Lovly, MD, PhD

Latest:

BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation to Address the Evolved Landscape of EGFR Mutant NSCLC

Christine Lovly, MD, PhD, shares data on BDTX-1535, a “masterkey” EGFR inhibitor targeting classical, non-classical, and the C797S resistance mutation in patients with EGFR mutant non-small cell lung cancer (NSCLC), from a presentation at AACR 2024.

Chika Nwachukwu, MD, PhD

Latest:

Drs Gerber and Nwachukwu on the Importance of Streamlining Clinical Research in Cancer Care

David Gerber, MD, and Chika Nwachukwu, MD, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

University of North Carolina, Lineberger Comprehensive Cancer Center

Latest:

Robert L. Ferris, MD, PhD, Appointed Executive Director of UNC Lineberger Comprehensive Cancer Center

Robert L. Ferris, MD, PhD, has been named the executive director of UNC Lineberger Comprehensive Cancer Center and UNC system chief of oncology services.

Dan Vogl, MD, MSCE

Latest:

Dr. Vogl on the Utilization of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma

Dan Vogl, MD, MSCE, discusses the utilization of modakafusp alfa in relapsed/refractory multiple myeloma.

Junjie Li, MD

Latest:

Dr Li on Neoadjuvant SHR-A1811 in HER2+ Breast Cancer

Junjie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer.

Oliva Lara, MD

Latest:

Dr. Lara on Role of Molecular Differences in Disparities in Uterine Serous Carcinoma

Oliva Lara, MD, discusses the connection between molecular differences and disparities in cancer care in uterine serous carcinomas, as examined in a retrospective cohort study.

Linda Fleisher, PhD, MPH

Latest:

Drs Edelman and Fleisher on Personalizing and Adapting Treatment Approaches in Clinical Trials

Martin Edelman, MD, and Linda Fleisher, PhD, MPH, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.

Rasha Cosman, BSc, MBBS, FRACP

Latest:

Dr Cosman on the Potential Utility of MT-302 in TROP-2–Expressing Epithelial Cancers

Rasha Cosman, BSc, MBBS, FRACP, discusses the mechanism of action and potential role for the in vivo mRNA CAR therapy MT-302 in TROP-2–expressing epithelial cancers.

Association of Community Cancer Centers

Latest:

ACCC Releases Trending Now in Cancer Care

The Association of Community Cancer Centers today released its annual Trending Now in Cancer Care report, including actionable strategies in 8 key areas.

Danai Dima, MD

Latest:

Dr Dima on Real-World Responses With Teclistamab in R/R Multiple Myeloma

Danai Dima, MD, discusses real-world responses with teclistamab in relapsed/refractory multiple myeloma.

Syed Abbas Ali, MBBS

Latest:

Dr Ali on the Need for Novel Targets Beyond BCMA in Multiple Myeloma

Syed Abbas Ali, MBBS, discusses the identification of novel targets for patients with multiple myeloma who previously progressed on BCMA-targeted agents.

Jerry Le Pow Spivak, MD

Latest:

Dr. Spivak on Diagnosing Essential Thrombocythemia

Jerry Le Pow Spivak, MD, discusses diagnosing essential thrombocythemia.

Courtney DiNardo, MD, The University of Texas MD Anderson Cancer Center

Latest:

Treatment Approaches for TP53-Mutated AML

Key opinion leaders in hematology oncology share insights into the challenges associated with treating patients with TP53-mutated AML and highlight the recent FDA breakthrough designation of eprenetapopt.

Leonard Augenlicht, PhD

Latest:

The Microbiome and Colon Cancer: Dietary Influence on Incidence, Morbidity, and Mortality

One of the prime risk factors for CRC is the consumption of a high-risk, Western-style diet high in processed foods, refined grains, red meat, and sugar.